Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
m |
|||
| Line 12: | Line 12: | ||
*2018-11-22: Initial authorization | *2018-11-22: Initial authorization | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| + | *2012-03-30: Initial approval for the treatment of recurrent or relapsed CCR4-positive [[adult T-cell leukemia-lymphoma|adult T-cell leukemia/lymphoma]]. | ||
*2014-03-17: new additional indications for the treatment of relapsed or refractory CCR4-positive [[peripheral T-cell lymphoma]] and relapsed or refractory CCR4-positive [[cutaneous T-cell lymphoma]]. | *2014-03-17: new additional indications for the treatment of relapsed or refractory CCR4-positive [[peripheral T-cell lymphoma]] and relapsed or refractory CCR4-positive [[cutaneous T-cell lymphoma]]. | ||
*2014-12-18: Revised indication and a new dosage for the treatment of CCR4-positive [[adult T-cell leukemia-lymphoma|adult T-cell leukemia/lymphoma]]. | *2014-12-18: Revised indication and a new dosage for the treatment of CCR4-positive [[adult T-cell leukemia-lymphoma|adult T-cell leukemia/lymphoma]]. | ||
| Line 26: | Line 27: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | |||
[[Category:Anti-CCR4 antibodies]] | [[Category:Anti-CCR4 antibodies]] | ||
| Line 37: | Line 37: | ||
[[Category:EMA approved in 2018]] | [[Category:EMA approved in 2018]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
| + | [[Category:PMDA approved in 2012]] | ||
Revision as of 01:10, 10 June 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. [1][2][3]
Diseases for which it is used
History of changes in FDA indication
- 2018-08-08: Initial approval for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (Based on MAVORIC)
History of changes in EMA indication
- 2018-11-22: Initial authorization
History of changes in PMDA indication
- 2012-03-30: Initial approval for the treatment of recurrent or relapsed CCR4-positive adult T-cell leukemia/lymphoma.
- 2014-03-17: new additional indications for the treatment of relapsed or refractory CCR4-positive peripheral T-cell lymphoma and relapsed or refractory CCR4-positive cutaneous T-cell lymphoma.
- 2014-12-18: Revised indication and a new dosage for the treatment of CCR4-positive adult T-cell leukemia/lymphoma.
- 2018-08-21: new indications and a new dosage for the treatment of relapsed or refractory cutaneous T-cell lymphoma.
Also known as
- Code name: KW-0761
- Generic name: mogamulizumab-kpkc
- Brand name: Poteligeo